Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia.
about
Corneal molecular and cellular biology update for the refractive surgeon.BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivoTrichostatin a inhibits corneal haze in vitro and in vivo.One-year outcomes of a bilateral randomised prospective clinical trial comparing PRK with mitomycin C and LASIK.Dose-dependent effect of mitomycin C on human vocal fold fibroblastsEfficacy and safety of mitomycin C as an agent to treat corneal scarring in horses using an in vitro model.Isolation and cultivation of equine corneal keratocytes, fibroblasts and myofibroblasts.Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis).Effectiveness of scraping and mitomycin C to treat haze after myopic photorefractive keratectomyMitomycin C: a promising agent for the treatment of canine corneal scarringTwo-step versus Single Application of Mitomycin-C in Photorefractive Keratectomy for High MyopiaEffect of Mitomycin C on Myopic versus Astigmatic Photorefractive Keratectomy.Improving patient outcomes following glaucoma surgery: state of the art and future perspectives.Corneal Regeneration After Photorefractive Keratectomy: A Review.Current and Future Techniques in Wound Healing Modulation after Glaucoma Filtering SurgeriesLong term followup of photorefractive keratectomy with adjuvant use of mitomycin C.KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis.
P2860
Q30865099-92238050-9864-487F-86DA-6A24E7F36286Q31120997-2A78896D-24C5-427B-A30B-905D7C8BEB46Q33402864-A27DB2C0-F821-4976-BBB8-8DE0BF6A0AC5Q33514987-690B86A0-2774-47A1-A067-7102ACD7FF35Q33960487-D68A5560-135C-4D65-95A7-A6AB6F3E432EQ33997504-CE0C80C3-B8F8-45DC-BFC3-4CCB17790315Q34092134-C79271EC-140D-426B-80BF-19FC40A42714Q34130123-6E4403F1-0DC8-4C03-81DF-5AF1E1CFFA0BQ34134050-49BF5577-6935-4DD4-B865-5B91FD79B327Q35967076-88EB4155-B848-4D33-8C6B-82AFC13FA96CQ36052259-9A95759D-59C8-4B9C-9B34-A08CE2FA1128Q37723742-ED8F29D4-FF1E-4385-ACE1-D4991798D52EQ38212219-CF5EB536-4A23-4135-8BE1-4884C9A6C664Q38274711-9D14C9FF-3917-40B5-B8C4-FA2E11636880Q38788689-EB294F2D-D649-4A36-9354-38C1616FAB25Q39585096-04555331-5D12-43FF-81D2-A92C6E8B567BQ52648806-6E10066F-4A81-4906-8A91-B8E568907AA7
P2860
Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Comparison of standard (0.02%) ...... g surface ablation for myopia.
@ast
Comparison of standard (0.02%) ...... g surface ablation for myopia.
@en
Comparison of standard
@nl
type
label
Comparison of standard (0.02%) ...... g surface ablation for myopia.
@ast
Comparison of standard (0.02%) ...... g surface ablation for myopia.
@en
Comparison of standard
@nl
prefLabel
Comparison of standard (0.02%) ...... g surface ablation for myopia.
@ast
Comparison of standard (0.02%) ...... g surface ablation for myopia.
@en
Comparison of standard
@nl
P2093
P1476
Comparison of standard (0.02%) ...... ng surface ablation for myopia
@en
P2093
Ivey Thornton
Ronald R Krueger
P304
P356
10.3928/1081597X-20080101-13
P577
2008-01-01T00:00:00Z